Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001213900-25-021165
Filing Date
2025-03-06
Accepted
2025-03-06 16:02:05
Documents
122
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 ANNUAL REPORT ea0230445-10k_orukathe.htm   iXBRL 10-K 2354570
2 DESCRIPTION OF SECURITIES ea023044501ex4-1_orukathe.htm EX-4.1 35667
3 FORM OF PRE-FUNDED WARRANT, DATED AUGUST 29, 2024 ea023044501ex4-3_orukathe.htm EX-4.3 84585
4 AMENDED AND RESTATED EMPLOYMENT LETTER AGREEMENT BY AND BETWEEN ORUKA THERAPEUTI ea023044501ex10-17_orukathe.htm EX-10.17 64901
5 AMENDED AND RESTATED EMPLOYMENT LETTER AGREEMENT BY AND BETWEEN ORUKA THERAPEUTI ea023044501ex10-18_orukathe.htm EX-10.18 64180
6 FORM OF INDEMNIFICATION AGREEMENT ea023044501ex10-19_orukathe.htm EX-10.19 60880
7 NON-EMPLOYEE DIRECTORS COMPENSATION PROGRAM ea023044501ex10-20_orukathe.htm EX-10.20 6137
8 IL-17 LICENSE AGREEMENT BY AND BETWEEN PARAGON THERAPEUTICS, INC. AND ORUKA THER ea023044501ex10-29_orukathe.htm EX-10.29 264577
9 IL-23 LICENSE AGREEMENT BY AND BETWEEN PARAGON THERAPEUTICS, INC. AND ORUKA THER ea023044501ex10-31_orukathe.htm EX-10.31 266790
10 CELL LINE LICENSE AGREEMENT BY AND BETWEEN WUXI BIOLOGICS IRELAND LIMITED AND OR ea023044501ex10-32_orukathe.htm EX-10.32 85539
11 AMENDMENT NO. 1 TO THE CELL LINE LICENSE AGREEMENT BY AND BETWEEN WUXI BIOLOGICS ea023044501ex10-33_orukathe.htm EX-10.33 13150
12 INSIDER TRADING POLICY ea023044501ex19-1_orukathe.htm EX-19.1 118955
13 LIST OF SUBSIDIARIES OF THE REGISTRANT ea023044501ex21-1_orukathe.htm EX-21.1 1967
14 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ea023044501ex23-1_orukathe.htm EX-23.1 1679
15 CERTIFICATION ea023044501ex31-1_orukathe.htm EX-31.1 10131
16 CERTIFICATION ea023044501ex31-2_orukathe.htm EX-31.2 9724
17 CERTIFICATION ea023044501ex32-1_orukathe.htm EX-32.1 4597
18 INCENTIVE COMPENSATION CLAWBACK POLICY ea023044501ex97-1_orukathe.htm EX-97.1 36056
24 GRAPHIC image_001.jpg GRAPHIC 55273
25 GRAPHIC image_002.jpg GRAPHIC 184389
26 GRAPHIC image_003.jpg GRAPHIC 147984
27 GRAPHIC image_003a.jpg GRAPHIC 70063
28 GRAPHIC image_004.jpg GRAPHIC 39573
29 GRAPHIC image_005.jpg GRAPHIC 46697
30 GRAPHIC image_006.jpg GRAPHIC 51283
31 GRAPHIC image_007.jpg GRAPHIC 58482
32 GRAPHIC ex10-17_001.jpg GRAPHIC 34126
33 GRAPHIC ex10-18_001.jpg GRAPHIC 35538
34 GRAPHIC ex19-1_001.jpg GRAPHIC 20082
35 GRAPHIC ex97-1_001.jpg GRAPHIC 20938
  Complete submission text file 0001213900-25-021165.txt   12618504

Data Files

Seq Description Document Type Size
19 XBRL SCHEMA FILE orka-20241231.xsd EX-101.SCH 83439
20 XBRL CALCULATION FILE orka-20241231_cal.xml EX-101.CAL 45629
21 XBRL DEFINITION FILE orka-20241231_def.xml EX-101.DEF 395007
22 XBRL LABEL FILE orka-20241231_lab.xml EX-101.LAB 701513
23 XBRL PRESENTATION FILE orka-20241231_pre.xml EX-101.PRE 421239
124 EXTRACTED XBRL INSTANCE DOCUMENT ea0230445-10k_orukathe_htm.xml XML 1077648
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-22873 | Film No.: 25715110
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)